Pharmacological management of diabetes is categorized into distinct therapeutic domains: insulin-based therapy for Type 1 Diabetes and oral antihyperglycemics for Type 2 Diabetes, characterized by specific pharmacokinetic profiles (peak time, duration) and molecular mechanisms such as hepatic gluconeogenesis inhibition or SGLT2 reabsorption blockade. The theoretical framework relies on identifying drug classes based on suffix nomenclature to predict their unique adverse effect profiles, including metabolic acidosis risks associated with metformin in renal insufficiency, hypoglycemia from insulin secretagogues, and infection susceptibility caused by glycosuria or altered intestinal motility.
Pharmacological management of diabetes is categorized into distinct therapeutic domains: insulin-based therapy for Type 1 Diabetes and oral antihyperglycemics for Type 2 Diabetes, characterized by sp…